ProfileGDS5678 / 1416875_at
TitleAnti-VEGF and Anti-Notch treatment effect on U87 glioblastoma xenograft tumors [Mouse430_2]
OrganismMus musculus


control bevacizumab dibenzazepine GSM967852 GSM967853 GSM967854 GSM967855 GSM967856 GSM967862 GSM967863 GSM967864 GSM967865 GSM967857 GSM967858 GSM967859 GSM967860 GSM967861 31% 33% 32% 72% 34% 29% 30% 43% 33% 33% 32% 34% 32% 33% sort by agent Gene Expression Profile
Graph caption help
SampleTitleValueRank
GSM967852U87-EV human glioblastoma xenograft - Control 12.7267831
GSM967853U87-EV human glioblastoma xenograft - Control 22.7410333
GSM967854U87-EV human glioblastoma xenograft - Control 32.7197532
GSM967855U87-EV human glioblastoma xenograft - Control 44.6225772
GSM967856U87-EV human glioblastoma xenograft - Control 52.7226534
GSM967862U87-EV human glioblastoma xenograft - Bevacizumab treated 12.7301629
GSM967863U87-EV human glioblastoma xenograft - Bevacizumab treated 22.7382930
GSM967864U87-EV human glioblastoma xenograft - Bevacizumab treated 32.9883943
GSM967865U87-EV human glioblastoma xenograft - Bevacizumab treated 42.7227533
GSM967857U87-EV human glioblastoma xenograft - dibenzazepine treated 12.7299833
GSM967858U87-EV human glioblastoma xenograft - dibenzazepine treated 22.7237932
GSM967859U87-EV human glioblastoma xenograft - dibenzazepine treated 32.7302734
GSM967860U87-EV human glioblastoma xenograft - dibenzazepine treated 42.724932
GSM967861U87-EV human glioblastoma xenograft - dibenzazepine treated 52.7341733